Open at the publisher →
In force since 2025-10-01, as the publisher states.
Copy read on 2026-11-10. The page it was read from
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.
sha256 601204d8f6d207ad51c72769677dfa0da17495e4c77ea21beaed71e2cf85f9d2
3 provisions
Title and introductory text
2025 No. 987
NATIONAL HEALTH SERVICE, ENGLAND
The National Health Service (General Medical Services Contracts) (Prescription of Drugs etc.) (Amendment) Regulations 2025
Made
at 3.00 p.m. on 1st September 2025
Laid before Parliament
at 5.05 p.m. on 1st September 2025
Coming into force
1st October 2025
The Secretary of State makes these Regulations in exercise of the powers conferred by sections 88(1) and (2) and 272(7) and (8) of the National Health Service Act 2006.
Propose a change1 Citation, commencement, extent and application
(1) These Regulations may be cited as the National Health Service (General Medical Services Contracts) (Prescription of Drugs etc.) (Amendment) Regulations 2025.
(2) These Regulations come into force on 1st October 2025.
(3) These Regulations extend to England and Wales and apply in relation to England only.
Propose a change2 Amendments to Schedule 2 to the National Health Service (General Medical Services Contracts) (Prescription of Drugs etc.) Regulations 2004
In Schedule 2 to the National Health Service (General Medical Services Contracts) (Prescription of Drugs etc.) Regulations 2004 (drugs, medicines and other substances that may be ordered only in certain circumstances)—
(a) in column 1 of the table (drugs), in the entry relating to drugs for the treatment of erectile dysfunction, omit “Tadalafil” and “Vardenafil”;
(b) in column 1 of the table, in the entry relating to drugs for the treatment of erectile dysfunction, after the entry for “Avanafil” insert “Cialis” and “Levitra”;
(c) in column 2 of the table (patient), in the entry relating to “Oseltamivir (Tamiflu)” omit sub-paragraph (a) in paragraphs (1) and (2) and in the entry relating to “Zanamivir (Relenza)” omit sub-paragraph (a) in paragraph (1).
Propose a change